Close

Zafgen (ZFGN) Starts Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes

September 12, 2017 4:06 PM EDT Send to a Friend
Zafgen, Inc. (Nasdaq: ZFGN), today announced initiation of ZAF-1061-201, the Company’s Phase 2 clinical trial evaluating ZGN-1061 in patients with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login